| Literature DB >> 30613574 |
Cheol Soo Yoon1, Min Keun Kim2, Yeon Sook Kim3, Suk Keun Lee1.
Abstract
BACKGROUND: Coffee extract has been investigated by many authors, and many minor components of coffee are known, such as polyphenols, diterpenes (kahweol and cafestol), melanoidins, and trigonelline, to have anti-inflammatory, anti-oxidant, anti-angiogenic, anticancer, chemoprotective, and hepatoprotective effects. Therefore, it is necessary to know its pharmacological effect on hepatocytes which show the most active cellular regeneration in body.Entities:
Keywords: Cellular regeneration; IP-HPLC; Murine hepatocytes; Protein expressions
Year: 2018 PMID: 30613574 PMCID: PMC6308107 DOI: 10.1186/s40902-018-0183-z
Source DB: PubMed Journal: Maxillofac Plast Reconstr Surg ISSN: 2288-8101
Calculation of DCE doses for a mouse to achieve equivalence with human adults
| Coffee | Ordinary coffee extract | Dialyzed coffee extract (DCE) |
|---|---|---|
| Caffeine concentration | 120 mg/150 mL | 60 mg/150 mL |
| Dialysis coefficient | 50% | |
| One cup for a human adult (60 kg, 59.4 L) | 150 mL | 300 mL (DCE-1) |
| DCE-1 to 30 g mouse | 0.15 mL | |
| DCE-2.5 to 30 g mouse | 0.375 mL | |
| DCE-5 to 30 g mouse | 0.75 mL | |
| DCE-10 to 30 g mouse | 1.5 mL |
Antibodies used in the study
| Signaling proteins | No. | Antibodies |
|---|---|---|
| Proliferation-related proteins | 11 | Ki-67*, PCNAa, CDK4a, PLK4a, lamin A/C, MPM2a, cyclin D2, p14, p16a, p21a, p27a |
| cMyc/MAX/MAD network proteins | 3 | cMyca, MAXa, MADa |
| p53/Rb/E2F signaling proteins | 5 (1) | p53, Rb-1#, E2F-1a, MDM2a, (CDK4) |
| Wnt/β-catenin signaling proteins | 5 | Wnt1a, β-catenina, APCa, snaila, TCF-1a |
| Epigenetic modification proteins | 6 | DMAP1a, histone H1a, KDM4D$, HDAC-10$, MBD4a, DNMT1a |
| Protein translation proteins | 5 | DOHHa, DHSa, elF5A-1$, elF5A-2$, eIF2AK3a |
| Growth factor proteins | 16 | FGF-1a, FGF-2a, HGF-1a, TGF-β1#, TGF-β2, SMAD4a, IGF-1a, IGFIIRa, GHa, GHRHa, HER1a, HER2a, Erβa, insulin@, Meta, CTGFa |
| RAS signaling proteins | 12 | NRAS$, KRAS$, STAT3a, SOS-1a, SOS-2a, RAF-Ba, JNK-1a, ERK1a, p-ERK$, MEKKa, pAKT1/2/3, PI3Ka |
| NFkB signaling proteins | 12 (2) | NFkBa, IKKa, GADD45a, GADD153, MDRa, mTOR@, p38a, p-p38a, AMPK, PGC-1α, (ERK1a, p-ERKa) |
| Cellular stress and adaptation proteins | 16 (8) | LC3a, PLC-β2a, PKCa, p-PKCa, AKAPa, NFAT5a, leptina, HXK IIa, (pAKT1/2/3a, p38a, GADD45a, PI3Ka, MDM2a, mTORa, ERK-1a, MDRa) |
| Inflammatory proteins upregulated | 13 (2) | IL-8, IL-12a, CD31a, COX1, α1-AT, LL-37, hepcidina, (TGF- β1#, TGF- β2), MMP-1a, MMP-3a, MMP-9a, MMP-10a |
| Inflammation proteins downregulated | 17 | TNFα@, IL-1a, IL-6a, IL-10a, IL-28a, M-CSFa, lysozymea, COX-2a, CD56a, CD68a, CD99a, cathepsin Ca, cathepsin Ga, CRP-1a, lactoferrina, MMP-2a, MMP-12a |
| Cellular differentiation proteins | 11 | TGase-2$, p63$, caveolina, Jagged2a, Notch 1a, GLI-1a, Muc1a, Muc4a, AP-1a, SP-1a, SP-3a |
| Antioxidant and protection-related | 11 (2) | HO-1a, SOD-1a, GST-1a, NOS-1$, LC3a, HSP-27a, HSP-70a, HSP-90a, (leptina, hepcidin), NRF2a |
| p53-mediated apoptosis proteins | 13 (2) | BCL2a, BAXa, BADa, BAKa, BIDa, AIFa, APAF-1a, caspase 9a, c-caspase 9a, PARPa, c-PARPa(p53a, MDM2a) |
| FAS-mediated apoptosis proteins | 9 (1) | FASLa, FASa, FADDa, FLIPa, caspase 8a, caspase 3a, c-caspase 3a, (BID) |
| Oncogenic proteins | 12 (4) | PTEN&, DMBT-1a, CEAa, 14–3-3a, survivin@, YAPa 1, TERTa, (pAKT1/2/3a, MBD4a, Muc1a, Muc4a), ATMa |
| Angiogenesis-related proteins | 17 (4) | HIF&, VEGF-Aa, VEGF-Ca, angiogenin$, LYVE-1a, CMG2$, vWF$, FLT-4$, ET-1a, PAI-1a, plasminogen, PDGF-Aa, VCAMa, (COX-1a, leptina, CD31, FGF-2a) |
| Control housekeeping proteins | 3 | α-tubulina, β-actina, GAPDHa |
| Total | 223 (26) | tTotal 197 antibodies |
The number inside the parenthesis represents the antibodies overlapped
aSanta Cruz Biotechnology, USA
#DAKO, Denmark
$Neomarkers, CA, USA
@ZYMED, CA, USA
&Abcam, Cambridge, UK
Abbreviations: α1-AT α-1 antitrypsin; AMPK AMP-activated protein kinase; p-AKT1/2/3 phosphorylated (p-Akt, Thr 308); APAF-1 apoptotic protease-activating factor 1; AP-1 activating protein-1; BAD BCL2 associated death promoter; BAK BCL2 antagonist/killer; BAX BCL2-associated X; BCL-2 B-cell leukemia/lymphoma-2; BID BH3 interacting-domain death agonist; c-caspase 3 cleaved-caspase 3, caveolin; CD31/56/68/99 cluster of differentiation 31/56/68/99; CDK4 cyclin-dependent kinase 4; CEA carcinoembryonic antigen; CMG2 capillary morphogenesis protein 2; COX-1 cyclooxygenase-2; COX-2 cyclooxygenase-2; c-PARP cleaved-PARP (poly-ADP ribose polymerase); CTGF connective tissue growth factor, cyclin D2; DMAP1 DNA methyltransferase 1-associated protein; DMBT1 deleted in malignant brain tumors 1; DOHH deoxyhypusine hydroxylase; DHS deoxyhypusine synthase; E2F-1 transcription factor; eIF2AK3 (PERK) eukaryotic translation initiation factor 2 (protein kinase R (PKR)-like endoplasmic reticulum kinase); elF5A-1 eukaryotic translation initiation factor 5A-1; elF5A-2 eukaryotic translation initiation factor 5A-2; ERβ estrogen receptor beta; ERK extracellular signal-regulated protein kinases; ET-1 endothelin-1; FAS; CD95/Apo1; FASL FAS ligand; FADD FAS associated via death domain; FGF-1 fibroblast growth factor-1; FLIP FLICE-like inhibitory protein; FLT-4 Fms-related tyrosine kinase 4; GADD45 growth arrest and DNA-damage-inducible 45; GAPDH glyceraldehyde 3-phosphate dehydrogenase; GH growth hormone; GHRH growth hormone-releasing hormone; GST-1 glutathione S-transferase-1; HDAC-10 hepcidin; HIF hypoxia inducible factor-1α; HO-1 heme oxygenase 1; HER2 human epidermal growth factor receptor 2; HGF hepatocyte growth factor; HSP-27/70/90 heat shock protein-27/70/90; HXK II hexokinase II; IKK IkappaB kinase, IGF-1, IGFIIR; IL-1/6/8/12/28 interleukin-1/6/8/12/28, Jagged2; JNK-1 Jun N-terminal protein kinase; KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; LC3 microtubule-associated protein 1A/1B-light chain 3, leptin; LYVE-1 lymphatic vessel endothelial hyaluronan receptor 1, MAX Myc-associated factor X; MBD4 methyl-CpG-binding domain protein 4; M-CSF macrophage colony-stimulating factor; MEKK MEK kinase; MDM2 mouse double minute 2 homolog; MDR multiple drug resistance; MPM2 mitotic protein monoclonal 2; mTOR mammalian target of rapamycin; cMyc V-myc myelocytomatosis viral oncogene homolog; NOS-1 nitric oxide synthase 1; NRAS neuroblastoma RAS viral oncogene homolog, Notch 1, p16, p21, p27, p38, p53, p63, PAI plasminogen activator inhibitor-1; PARP poly-ADP ribose polymerase; PCNA proliferating cell nuclear antigen, PDGF-A platelet-derived growth factor-A; PLC-β2 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterse β-2; PI3K phosphatidylinositol-3-kinases; PLK4 polo-like kinase 4 or serine/threonine-protein kinase; PKC protein kinase C, p-p38 phosphor-p38; PTEN phosphatase and tensin homolog; Rb-1 retinoblastoma-1; SMAD4 mothers against decapentaplegic; drosophila homolog 4; SOD-1 superoxide dismutase-1; SP-1 specificity protein 1; STAT3 signal transducer and activator of transcription-3; TGF-β1 transforming growth factor-β1; TERT human telomerase reverse transcriptase; TNF-α tumor necrosis factor-α, β-actin, 14-3-3; VEGF vascular endothelial growth factor; VCAM vascular cell adhesion, vWF Von Willebrand factor; YAP 1 yes-associated protein
Fig. 1Photomicrographs of mouse liver, hematoxylin and eosin stain. a Normal mouse liver. b Mouse liver treated with DCE-2.5, denoting hypertrophic hepatocytes with increased nuclear heterochromatism. c Mouse liver treated with DCE-5 had hypertrophic hepatocytes, which formed thick hepatic cords. d In the livers of mice treated with DCE-10, hepatocytes were slightly shrunken and aligned, and sinusoidal spaces were enlarged
Fig. 2Photomicrographs of mouse liver, immunohistochemical staining for GST-1, PARP, MMP-9, and HGF-1. a GST-1 expression was increased dose-dependently by DCE-2.5 to DCE-10. b PARP was markedly positive in the DCE-2.5 group. c MMP-9 was strongly positive in the DCE-2.5 group. d HGF-1 was gradually and dose-dependently increased by DCE
Fig. 3Expression levels of proliferation-related proteins (a), cMyc/MAX/MAD signaling proteins (b), p53/Rb/E2F signaling proteins (c), and Wnt1/β-catenin signaling proteins (d) after DCE treatment in mouse livers as determined by IP-HPLC. Major protein expression pattern induced by DCE-5 was found in the radial graphs of A2, B2, C2, and D2
Fig. 4Expressions of epigenetic modification-related proteins (a), protein translation-related proteins (b), growth factors (c), and RAS signaling proteins (d) after DCE treatment in mouse livers as determined by IP-HPLC. Major protein expression pattern induced by DCE-5 was found in the radial graphs of A2, B2, C2, and D2
Fig. 5Expressions of NFkB signaling (a), cellular stress and adaptation (b), and cellular differentiation (c) protein levels after DCE treatment in mouse livers as determined by IP-HPLC. Major protein expression pattern induced by DCE-5 was found in the radial graphs of A2, B2, C2, and D2
Fig. 6Expressions of inflammatory proteins upregulated (a), inflammatory proteins downregulated (b), p53-mediated apoptosis proteins (c), and FAS-mediated apoptosis proteins (d) after DCE treatment in mouse livers as determined by IP-HPLC. Major protein expression pattern induced by DCE-5 was found in the radial graphs of A2, B2, C2, and D2
Fig. 7Expressions of angiogenesis-related proteins (a), antioxidant and protection-related proteins (b), and oncogenic proteins (c) after DCE treatments of mouse livers as determined by IP-HPLC. Major protein expression pattern induced by DCE-5 was found in the radial graphs of A2, B2, C2, and D2
Fig. 8Global protein expression diagrams showing the effects of DCE-5 in mouse liver. Mouse livers treated with DCE-5 showed characteristic patterns of molecular signaling for up- (red round circles) and downregulating (blue round circles) essential proteins for cellular proliferation, protection, adaptation, differentiation, apoptosis, and regeneration